Les inhibiteurs de points de contrôle immunitaires sont une classe de médicaments qui combattent le système immunitaire du corps pour combattre les cellules cancéreuses. Cependant, la plupart des patients ne répondent pas à ces thérapies. Il existe une nouvelle classe de médicaments qui ciblent deux protéines impliquées dans la suppression de la réponse immunitaire de l'organisme contre les tumeurs.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from cancer with the molecule M7824. These researchers are also undertaking trials with those suffering from le cancer du pancréas and those infected with HPV.
There are many other trials and experiments being taken to treat and guérir le cancer more effectively in different research institutes. This drug with a dual approach will be a boon in the traitement du cancer, as with a single molecule, multiple therapies are included.
